Company: SNY
Filing Date: 2025-07-18
Form Type: SC TO-T/A
Source: 0001193125-25-160629
Chunk: 0

Company: Sanofi
Filing Date: 2025-07-18
Form: SC TO-T/A
Chunk 0
---
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 3) Blueprint Medicines Corporation (Name of Subject Company (Issuer)) ROTHKO MERGER SUB, INC. AVENTIS INC. SANOFI (Names of Filing Persons — Offerors) Common Stock, Par Value $0.001 Per Share (Title of Class of Securities) 09627Y109 (Cusip Number of Class of Securities) Roy Papatheodorou Executive Vice President, General Counsel, Head of Legal, Ethics & Business Integrity Sanofi 46, avenue de la Grande Armée, 75017 Paris, France Telephone: 011 + 33 1 53 77 40 00 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications on Behalf of Filing Persons) Copies to: Michael J. Aiello, Esq. Sachin Kohli, Esq. Weil, Gotshal & Manges LLP 767 Fifth Avenue New York, New York 10153 (212) 310-8000

| ☒ | Check the box if any part of the fee is offset as provided by Rule                                                                                                                                       
 0-11(a)(2) and identify the filing with which the offsetting fee was previously paid. Identify the previous filing by registration statement number, or the form or schedule and the date of its filing. |

| Amount Previously Paid: 1,465,193.42    |     | Filing Party: Sanofi, Aventis Inc. and Rothko Merger Sub, Inc. |
| Form or Registration No.: Schedule TO-T 
 (File No. 005-88827)                    |     | Date Filed: June 17, 2025                                      |

| ☐ | Check the box if the filing relates solely to preliminary communications made before the commencement of a 
 tender offer.                                                                                              |

Check the appropriate boxes below to designate any transactions to which the statement relates:

| ☒ | Third-party tender offer subject to Rule 14d-1. |

| ☐ | Issuer tender offer subject to Rule 13e-4. |

| ☐ | Going-private transaction subject to Rule 13e-3. |

| ☐ | Amendment to Schedule 13D under Rule 13d-2